- Home
- RAMP vs AZTA Comparison
RAMP vs AZTA Comparison
Compare RAMP & AZTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RAMP
- AZTA
- Stock Information
- Founded
- RAMP 2018
- AZTA 1978
- Country
- RAMP United States
- AZTA United States
- Employees
- RAMP N/A
- AZTA N/A
- Industry
- RAMP EDP Services
- AZTA Industrial Machinery/Components
- Sector
- RAMP Technology
- AZTA Technology
- Exchange
- RAMP Nasdaq
- AZTA Nasdaq
- Market Cap
- RAMP 2.0B
- AZTA 2.4B
- IPO Year
- RAMP 1987
- AZTA 1995
- Fundamental
- Price
- RAMP $32.19
- AZTA $52.63
- Analyst Decision
- RAMP Buy
- AZTA Buy
- Analyst Count
- RAMP 7
- AZTA 5
- Target Price
- RAMP $39.71
- AZTA $61.60
- AVG Volume (30 Days)
- RAMP 499.0K
- AZTA 595.5K
- Earning Date
- RAMP 02-06-2025
- AZTA 02-05-2025
- Dividend Yield
- RAMP N/A
- AZTA N/A
- EPS Growth
- RAMP N/A
- AZTA N/A
- EPS
- RAMP 0.04
- AZTA N/A
- Revenue
- RAMP $707,165,000.00
- AZTA $656,323,000.00
- Revenue This Year
- RAMP $13.82
- AZTA N/A
- Revenue Next Year
- RAMP $9.09
- AZTA $6.32
- P/E Ratio
- RAMP $738.15
- AZTA N/A
- Revenue Growth
- RAMP 13.84
- AZTA N/A
- 52 Week Low
- RAMP $21.45
- AZTA $38.82
- 52 Week High
- RAMP $42.10
- AZTA $69.16
- Technical
- Relative Strength Index (RSI)
- RAMP 63.92
- AZTA 64.67
- Support Level
- RAMP $27.99
- AZTA $50.79
- Resistance Level
- RAMP $31.90
- AZTA $53.47
- Average True Range (ATR)
- RAMP 0.80
- AZTA 1.78
- MACD
- RAMP 0.11
- AZTA 0.01
- Stochastic Oscillator
- RAMP 89.94
- AZTA 75.83
About RAMP LiveRamp Holdings Inc.
LiveRamp Holdings Inc is a global technology company that helps companies build enduring brand and business value by collaborating responsibly with data. A groundbreaking leader in consumer privacy, data ethics and foundational identity, LiveRamp offers a connected customer view with clarity and context while protecting brand and consumer trust.
About AZTA Azenta Inc.
Azenta Inc is a provider of life sciences solutions, enabling impactful breakthroughs and therapies to market faster. It provides a full suite of reliable cold-chain sample management solutions and genomic services across areas such as drug development, clinical research and cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. The company has three reportable segments that are Sample Management Solutions, Multiomics, and B Medical Systems. It generates a substantial part of its revenue from its Sample Management Solutions segment.